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Abstract: Inflammation is a common response of an individual against either exogenous or 
endogenous damage. The role of inflammation and of inflammatory cells recently emerged also in the 
pathogenesis of neurodegenerative disorders. Experimental evidences show how neurotransmitters, 
besides their role in the synapses, play a modulatory role during immune response. Drugs used for 
treatment of dementia symptoms are able to increase neurotransmitters levels, and likely to have a 
modulatory role during immune response. Aim of this review is to discuss the most recent advances on 
inflammation role during neurodegeneration and also to individuate the potential anti-inflammatory 
role played by drugs currently used for Alzheimer’s disease treatment. 
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INTRODUCTION 
 Inflammatory response is essential for the survival of an 
organism – it consists of a mechanism of self-defense 
triggered by the immune system against endogenous and 
exogenous damage. Inflammation must be closely regulated 
because an insufficient or an excessive response will lead to 
pathological conditions, such as immunodeficiency or 
chronic inflammatory diseases [1]. The role of inflammation 
in some acute brain pathologies, such as multiple sclerosis, 
encephalitis and acute neurodegeneration following ischemia 
or trauma, has been widely described [2]. By contrast, its 
role in some neurodegenerative diseases, such as 
Alzheimer’s disease (AD), is not clear.  
 The immune system is negatively influenced by aging. 
Normal human aging, which is the consequence of a 
dysfunction of self-organizing systems and of their reduced 
ability to adapt to the environment, has been associated with 
a loss of complexity in many anatomical structures and 
physiological processes [3]. Progressive changes in the 
immune system over a person’s lifespan have been reported 
to influence the capacity to respond to immune challenges. 
Both T-cell and B-cell systems are believed to be involved in 
this process [4-7]. These age-associated immune changes are 
called immunosenescence [8]. It has been hypothesized that 
human immunosenescence is characterized by a deterioration 
in adaptive immunity, whereas innate immunity is conserved 
or even up-regulated. These changes in the immune system 
may result from continual exposure to a range of potential 
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antigens, such as viruses, bacteria, food and self-molecules 
[9, 10]. Within this scenario, immunosenescence is believed 
to reduce the ability of older people to control infectious 
diseases. Furthermore, it has been hypothesized that the 
immune system is implicated, to a varying extent, in many 
age-related diseases. Indeed, the prevalence of cancer and 
chronic inflammatory and autoimmune diseases, as well as 
that of neurodegenerative diseases, is the highest in this 
phase of life [11]. By contrast, a good immune system in 
older people has been correlated with health status. One 
possible explanation for these findings may lie in the 
increased serum levels of inflammatory mediators, such as 
cytokines and acute phase proteins, observed in older people, 
which is indicative of a chronic low-grade inflammatory 
state [12]. The prolonged duration of this inflammatory state 
may damage several organs, including the brain. Chronic 
inflammation thus appears to be involved in the pathogenesis 
of all age-related diseases, including atherosclerosis, 
diabetes, heart disease and cancer [13, 14]. A growing body 
of evidence also suggests that inflammation plays an 
important role in various neurodegenerative diseases, to 
which AD has more recently been added [2, 15].  
 Acetylcholinesterase inhibitors (AChEIs) are widely used 
for the symptomatic treatment of AD. Although the primary 
action of all currently available AChEIs is based on their 
ability to inhibit acetylcholinesterase (AChE), the evidence 
suggests that they possess other mechanisms, such as an anti-
inflammatory effect, that may be exploited to treat AD. If so, 
AChEIs may to some extent be able to modify the disease 
course. The aim of this review is to provide an overview of 
the anti-inflammatory mechanism of AChEIs and a summary 
of their pharmacological profiles.  
INFLAMMATION IN ALZHEIMER’S DISEASE  
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 Although there is emerging evidence that the causes of 
AD often overlap the other forms of dementia, AD remains 
the most common cause of dementia, accounting for 60-80% 
of cases. It is estimated that approximately 34 million people 
worldwide have AD [16]. The two main neuropathological 
hallmarks of AD are extracellular amyloid-beta (Aβ) plaques 
and intracellular neurofibrillary tangles accompanied by 
reactive microgliosis, dystrophic neuritis and loss of neurons 
and synapses [17]. According to the Aβ hypothesis, the 
aggregation of Aβ has been identified as the crucial factor in 
the development of the disease, whereas brain inflammation 
is considered to be a response aimed at eliminating the initial 
cause of cell injury as well as necrotic cells and tissue. 
Although the underlying causes of these changes remain 
unknown, aging and genetic factors are believed to play the 
most important role. Inflammation has consequently long 
been considered to be a pathological hallmark of AD, though 
not to play an active role in the pathogenesis of the disease. 
However, emerging evidence suggests that inflammation 
does instead play an active role in the pathogenesis of this 
disease through certain reactions, such as those associated 
with Aβ plaques and neurofibrillary tangles [18].  
 The cells responsible for this inflammatory reaction are 
microglia and astrocytes [15]. The main role of microglia is 
to surveil brain tissue for the presence of pathogens and 
cellular debris as well as to maintain the plasticity of 
neuronal circuits [19]. In normal healthy brain, microglial 
cells display a typical down-regulated phenotype when 
compared with other tissue macrophages, but rapidly react in 
response to a number of acute and chronic insults. Activated 
microglial cells may cause neuronal damage by releasing 
free radicals as well as cytokines and toxic factors. 
Alternatively, microglia may exert neuroprotective functions 
by secreting growth factors or diffusible anti-inflammatory 
mediators, which help to resolve inflammation and restore 
tissue homeostasis [20]. In AD brain, microglia link Aβ via 
cell-surface receptors, thereby leading to the production of 
pro-inflammatory cytokines and chemokines [21-23]. At the 
same time, microglia start to engulf Aβ fibrils by 
phagocytosis in response to receptor ligation. These 
mechanisms ultimately lead to the activation of a chronic 
inflammatory reaction [23]. Inflammatory mediators, in turn, 
increase the production of the Aβ42 peptide, which induces 
the expression of pro-inflammatory cytokines in glial cells in 
a vicious cycle [24]. These results support the role of 
microglia in the chronic inflammation present in most 
neurodegenerative diseases, including AD. In these 
pathophysiological conditions, microglia may remain 
activated for many years, during which they secrete various 
inflammatory factors. The contribution of blood-derived 
mononuclear cells that infiltrate the central nervous system 
(CNS) is also unclear within this scenario. There is, 
however, evidence pointing to an involvement of the 
systemic immune response in the pathogenesis of AD. In 
particular, animal studies have shown infiltration of blood-
derived cells in AD brain, while other studies have suggested 
that peripheral mononuclear phagocytes reduce the 
development of Aβ plaques [25]. There is also evidence 
indicating that peripheral blood mononuclear cells exert their 
effect without entering the CNS. In particular, peripheral 
blood mononuclear cells in AD patients produce higher 
levels of pro-inflammatory cytokines than those in normal 
subjects [26]. Furthermore, reports of changes in lymphocyte 
distribution and in cytokine levels in the plasma of AD 
patients point to the involvement of the immune system in 
AD [27]. 
 All these findings suggest that it may be possible to treat 
AD by means of anti-inflammatory drugs. This 
pharmacological approach is also supported by the results of 
epidemiological studies showing that non-steroid anti-
inflammatory drug (NSAID) treatment confers protective 
effects associated with a reduced incidence of AD [28, 29]. 
Anti-inflammatory randomized controlled trials have, 
however, yielded negative results. The drugs tested include 
prednisone, hydroxychloroquine, indomethacin, tarenflurbil 
and inhibitors of COX-1 and COX-2 [30-35]. 
INFLAMMATION AND THE CHOLINERGIC 
SYSTEM 
 One important endogenous mechanism that regulates the 
inflammatory response is a cross-talk between the immune 
and nervous systems. Numerous reports suggest that 
acetylcholine (ACh) might function as an important 
modulator of cellular interactions and immune functions [36, 
37]. In particular, electric stimulation of the vagus nerve has 
been shown to attenuate inflammation during endotoxemia in 
rats [38]. Moreover, ACh, the main vagal neurotransmitter, 
deactivates peripheral macrophages and inhibits the release 
of pro-inflammatory mediators. In human macrophage 
cultures, ACh significantly reduces the release of pro-
inflammatory cytokines, such as interleukin (IL)-1β, IL-6, 
IL-18 and tumor necrosis factor (TNF), without affecting the 
release of IL-10, an anti-inflammatory cytokine [38]. In the 
peripheral nervous system (PNS), acetylcholine-dependent 
macrophage deactivation is mediated by the α7 r subunit of 
the nicotinic acetylcholine receptor (nAChR), which is 
expressed in peripheral macrophages and has been described 
as being indispensable to the so-called “cholinergic anti-
inflammatory pathway” [39]. A brain cholinergic pathway 
that regulates microglia activation through α7 nAChRs has 
consequently been hypothesized [40, 41]. In addition to 
neurons and peripheral macrophages, several studies have 
demonstrated the expression of nAChRs in cell types both 
within and outside the nervous system [42]. Cultured 
hippocampal astrocytes express functional α7 receptors [43] 
while cortical astrocytes express both nicotinic and 
muscarinic receptors [44]. These data suggest that ACh may 
have an active role in attenuating inflammation in both brain 
and periphery.  
ACETYLCHOLINESTERASE INHIBITORS 
 The pathogenesis of AD has for many years been linked 
to a deficit of the neurotransmitter Ach in the brain. This 
hypothesis is supported by evidence indicating that cognitive 
impairment is correlated with cholinergic system 
dysfunctions [45]. A reduction in a number of cholinergic 
markers, such as choline acetyltransferase, ACh receptor 
bindings and ACh concentrations in the synaptic space, has 
been reported [46]. Over the years, it has been emerged that 
cholinergic dysfunction is not a primary neuropathological 
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hallmark of disease but rather a consequence of brain 
degeneration. Nevertheless, clinical trials based on a strategy 
aimed at correcting the ACh system dysfunction led to the 
first licensed medication for AD. Three AChEIs are currently 
being used to treat patients affected by AD: donepezil, 
galantamine and rivastigmine. All three AChEIs are licensed 
for the treatment of mild to moderate AD, though donepezil 
is also approved for severe AD in the USA. Rivastigmine is 
also approved for the treatment of dementia associated with 
Parkinson’s disease by North America and European 
regulatory agencies. Tacrine, the first AChEI on the market, 
has been replaced with other AChEIs owing to its serious 
adverse effects [47]. Another AChEI proposed is huperzine 
A, which has been approved for the treatment of mild to 
moderate AD in China, though not in North America or in 
European Countries. Huperzine A has displayed some 
benefits on dementia symptoms, though the results are 
inconclusive because of weaknesses in the methodology 
adopted for the clinical trials [48]. A phase II clinical trial 
yielded a significant effect on cognition though not on 
function or global status [49].  
 The use of AChEIs has been shown to have a significant, 
albeit modest, therapeutic effect on dementia symptoms, 
including activities of daily living, with no significant 
difference emerging between the three AChEIs [50, 51]. 
Furthermore, only 15-35% of all AD patients treated with 
AChEIs respond to these drugs. Several reasons have been 
suggested to explain the inter-individual variability of the 
drug response to AChEIs, such as co-morbidities, drug 
interactions, compliance, adverse reactions, genetic 
variations [52]. The mechanism of action underlying AChEIs 
is the inhibition of AChE, which reduces the breakdown of 
ACh in the synaptic cleft. Two forms of cholinesterase are 
present in humans, i.e. butyrylcholinesterase (BuChE) and 
AChE, which are predominant in the PNS and CNS, 
respectively [53]. While the physiological function of 
BuChE is not yet clear, AChE concludes the action of ACh 
by hydrolyzing it to choline and acetate [54]. The AChE in 
the brain has two forms, i.e. monomeric G1 and tetrameric 
G4. In AD brain it is only the latter form that displays a 
selective reduction of its activity [55].  
 Very few studies have been planned to investigate the 
anti-inflammatory capacity of AChEIs in patients affected by 
AD. Richardson and colleagues [56] examined the long-term 
use of AChEIs on pro-inflammatory cytokines in the 
periphery in AD patients. They did not find any difference 
between patients treated with AChEIs and drug naïve 
patients in relation to the concentrations of IL-1β, IL-6 and 
TNF-α. Furthermore, the levels of cytokines did not differ 
among the three AChEIs: donepezil, galantamine and 
rivastigmine. Some limitations of the study such as the lack 
of longitudinal follow-up and the small sample may have 
influenced these results that are in contrast to animal studies 
that suggest an anti-inflammatory role for AChEIs. 
Therefore, a more detailed pharmacological profile of each 
AChEI may help to better understand their potential anti-
inflammatory action. 
Donepezil 
 Donepezil binds to AChE in a reversible and non-
competitive manner, without involving BuChE inhibition. 
Due to its long plasma half-life, approximately 70 hours, 
donepezil can be administered once daily [57]. Immediate-
release tablets (5 mg and 10 mg) and a 23 mg sustained-
release tablets are available. Food intake doesn’t 
significantly influence the drug absorption. Donepezil is 
metabolized by the enzymes cytochrome P450 (CYP) 3A4 
and 2D6 in the liver, and the elimination of the parent drug 
and the metabolites is renal [58]. Clinical monitoring is 
therefore recommended when donepezil is administered 
together to other CYP3A4 and CYP2D6 inhibitors. Although 
some pharmacokinetic parameters are affected by aging, 
modification of donepezil dose is not necessary in the elderly 
[59]. Randomized clinical trial found significant beneficial 
effects on cognition, function, and global status for AD 
patients receiving donepezil 5 mg/day and 10 mg/day for 3-6 
months [50, 60-62]. The effect of donepezil on 
neuropsychiatric symptoms is rather controversial. Some 
meta-analysis showed a significant positive effect on 
behavioral in AD patients treated with donepezil [50, 60]. 
However, studies focused on the neuropsychiatric symptom 
treatment of AD patients did not find any significant 
difference between donepezil and placebo [63, 64]. 
Significant improvement in cognition in a dose-dependent 
manner was observed in a meta-analysis including 3320 AD 
patients treated with donepezil [62]. In this analysis a 
beneficial effect on global status, independent of dose, was 
also found. A 24-week, randomized, double-blind study 
found that donepezil 23 mg/day treatment provided a small 
but significant improvement in the cognition endpoint 
compared with donepezil 10 mg/day treatment in moderate 
to severe AD patients [65].  
 Recent experimental studies suggest that activated 
microglia may be one of the direct targets of donepezil in the 
central nervous system. Using purified microglia cultures 
and microglia cell lines, Hwang and colleagues [66] found 
that donepezil attenuated microglia production of nitric oxide 
and TNF-α and suppressed the gene expression of nitric 
oxide, IL-1β and TNF-α. In microglia/neuroblastoma 
coculture and animal model of neuroinflammation, they 
furthermore described the inhibitory effects of donepezil on 
microglial activation. It should be noted, however, that the 
concentration of donepezil used in these clinical experiments 
is much higher than that used clinically. These results were 
confirmed by Kim and colleagues [67] that examined the 
anti-inflammatory effect of donepezil against Aβ-oligomers 
and its neuroinflammatory mechanisms in cultured 
microglial cells and in mice. They found that donepezil 
significantly attenuated the release of inflammatory 
mediators from microglia and that it suppressed activated 
microglia-mediated toxicity in primary hippocampal cells. 
Further experimental studies have showed that donepezil was 
able to prevent pro-inflammatory cytokines, lipid 
peroxidation and memory impairments induced in mice brain 
by various substances [68-70]. Finally, eight months of 
donepezil treatment resulted in improvement of tau 
pathology, synaptic and neuronal loss as well as of 
neuroinflammation [70]. Interesting results have been found 
investigating peripheral blood mononuclear cells of patients 
affected by AD. Compared with untreated patients and 
healthy subjects, IL1β levels and expression were decreased 
as well as IL-4 levels and expression were significantly 
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higher in AD patients treated with donepezil, suggesting an 
active role of the drug in reducing peripheral inflammatory 
markers [71, 72].  
Galantamine 
 Galantamine is a competitive inhibitor of AChE and an 
allosteric modulator of nAChR [73]. It has a linear 
pharmacokinetics and approximately 7 hours plasma  
half-life [74]. In addition to a twice-daily immediate-release 
preparation, an extended-release capsule formulation of 
galantamine was developed, allowing once-daily 
administration [75]. Galantamine is metabolized by the CYP 
3A4 and 2D6, and the elimination of the parent drug and the 
metabolites is renal. About 30% of galantamine is excreted 
unchanged in the urine [76]. Galantamine clearance is 
decreased with aging [77]. When galantamine is 
administered together to other CYP3A4 and CYP2D6 
inhibitors, dose reduction may be required. Evidence 
suggests caution in the use of galantamine in patients with 
moderate impairment of hepatic function, and galantamine is 
not recommended in severe hepatic dysfunction [78].  
 Because of its capacity to modulate of nAChRs for 
improving nicotinic transmission, galantamine might interact 
with the cholinergic anti-inflammatory pathway [79]. At this 
regard, Pavlov and colleagues [80] reported evidence 
suggesting that the α7nAChR-mediated cholinergic anti-
inflammatory pathway is required for the anti-inflammatory 
effect of galantamine. They hypothesized that inhibition of 
brain AChE suppress systemic inflammation through a 
central muscarinic receptor-mediated and vagal- and 
α7nAChR-dependent mechanism. In agreement with these 
data, Liu ZH and colleagues [81] found that galantamine 
treatment (3 mg/Kg) reduced the level of circulating TNF-α 
in rats with lipopolysaccharide-induced peritonitis. At the 
same time, they reported evidence that the vagus nerve plays 
a role in the process of the action of galantamine. Further 
experimental studies described the role of neural cholinergic 
signaling in controlling inflammation and demonstrated that 
galantamine can reduce excessive pro-inflammatory 
cytochine release [80, 82, 83]. Finally, Takata and colleagues 
[84] showed that galantamine treatment facilitated Aβ 
clearance in brains of rodent AD models. They suggested 
that galantamine sensitizes microglial α7nAChRs to choline 
and induces calcium influx into microglia which in turn, may 
stimulate Aβ phagocytosis.  
Rivastigmine 
 Rivastigmine is an inhibitor of both AChE and BChE. It 
easily crosses the blood brain barrier and inhibits the AChE 
in a pseudo-irreversible way, due to its persistent action [85]. 
The inactivation of AChE enzyme last more than 24 hours, 
because of the carbamyl moiety of rivastigmine that remains 
bound to its substrate [86]. Rivastigmine has a very short 
plasma half-life of 1,5-2 hours. Since gastrointestinal adverse 
effects have been associated to the high plasma concentration 
values, it is recommended to administer rivastigmine with 
food. To improve the tolerability of rivastigmine, a 
transdermal path has been developed. This formulation 
gradually releases the drug over the 24 hours, avoiding 
significantly the wide fluctuation in the plasma concentration 
[87]. Rivastigmine is not significantly metabolized by 
hepatic microsomal enzymes, making drug-drug interactions 
unlikely [88]. Pharmacokinetic parameters are little 
influenced by aging but a dose titration of the drug must be 
performed according to its tolerability. A meta-analysis 
conducted by Cochrane collaboration found that only high 
dose of rivastigmine (6-12 mg daily) showed significant 
beneficial effects on cognition, function and global status 
[89]. Using low dose treatment (1-4 mg daily), a significant 
beneficial effect was only found on cognitive functions. No 
significant difference was found between rivastigmine and 
placebo in behavioral disturbances. In IDEAL study the 
effects of small transdermal rivastigmine patch (9.5 mg 
daily), large transdermal rivastigmine patch (17.4 mg daily) 
and oral rivastigmine capsules (6-12 mg daily) were 
compared [90]. All rivastigmine treatment groups showed 
significant improvement relative to placebo on cognition, 
behavior and global impression of change. The small patch 
had similar efficacy to the capsule, with approximately two-
thirds fewer reports of nausea and vomiting as well as no 
significant differences between the small transdermal 
rivastigmine patch and the large one were found. Other 
meta-analysis studies confirmed that rivastigmine has 
significant beneficial effects on cognition, function and 
global status [60, 62]. However, in a meta-analysis study, 
Raina and colleagues [50] reported that rivastigmine 
produces significant improvement only on global status in 
AD patients while the results regarding cognitive outcomes 
and functional abilities were inconsistent.  
 In experimental autoimmune encephalomyelitis, 
rivastigmine reduced demyelination, microglia activation 
and axonal damage as well as decreased the production of 
pro-inflammatory cytokines (TNF-α, Interferon-γ and IL-
17), without affecting IL-10 production [91]. These effects 
were abolished by α7nAChR antagonists, suggesting the 
implication of the cholinergic anti-inflammatory pathway in 
the process. The same conclusions were reported by Shifrin 
[92] that investigated the capacity of rivastigmine to improve 
the pathology of colitis in mice and rats by increasing the 
concentration of ACh in the brain and periphery. Rivastigmine 
significantly decreased the release of nitric oxide, TNF-α, 
IL-1β and IL-6 and this effect was abolished by α7 nicotinic 
receptor blockade. In AD patients treated with rivastigmine, 
IL-6 level was 47% lower than the average value of the AD 
patients treated with other drugs [93].  
CONCLUSION 
 Emerging evidence suggests that inflammation plays an 
active role in the pathogenesis of AD through certain 
reactions, such as those associated with Aβ plaques and 
neurofibrillary tangles and that ACh may have an active role 
in attenuating inflammation in both brain and periphery. A 
link between inflammation and cholinergic system has been 
identified in the anti-inflammatory role of vagus nerve. 
Experimental and animal studies showed that AChEIs inhibit 
the release of cytokines from microglia and monocytes. 
Surprisingly, there are very few researchers that investigated 
the effects of AChEIs on peripheral inflammatory cytokines 
in subjects affected by AD. The symptomatic efficacy of 
AChEIs is due to their augmentation of Ach-mediated 
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neuron-to-neuron transmission. However, we can 
hypothesize that the efficacy of AChEIs is, at least in part, 
due to an anti-inflammatory action. More research is now 
needed to clarify the anti-inflammatory role of AChEIs in 
AD patients and to define the mechanisms involved.  
LIST OF ABBREVIATIONS: 
Ach = AcetylCholine 
AChEI = AcetylCholine Esterase Inhibitors 
AD = Alzheimer’s Disease 
Aβ = Amyloid Beta 
BuChE = Butyrylcholine Esterase  
CNS = Central Nervous System 
IL = Interleukine 
NAChR = nicotinic Acetyl Choline Receptor 
NSAID = Nonsteroidal Antinflammatory Drugs 
PNS = Peripheral Nervous System  
TNF = Tumor Necrosis Factor 
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